Drugs / KBL693
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04307173 | Aug → Oct 2020 | asthma | KoBioLabs | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-03-17 | KoBioLabs | Results 고바이오랩, 마이크로바이옴 치료 신약 KBLP-002 글로벌 임상 1상 완료 kobiolabs.com ↗
또한 다회 투여 후 이학적 검사 및 활력 징후 등 종합적인 검사를 실시하여 뛰어난 안전성과 내약성 평가 결과를 확보하였다. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-09-07 | KoBioLabs | 고바이오랩, 면역질환 치료 신약 소재 KBL693 미국 특허 취득 kobiolabs.com ↗ |
| 2021-03-17 | KoBioLabs | 고바이오랩, 마이크로바이옴 치료 신약 KBLP-002 글로벌 임상 1상 완료 kobiolabs.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KBL693 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04307173 ↗ |
| Route | Oral | “Route of Administration: Oral” NCT04307173 ↗ |